- Autores: Devine G, Richard P, Sakuntabhai A, Sousa CA
- Ano de Publicação: 2014
- Journal: Lancet
- Link: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62071-7/abstract
The most recent dengue vaccine trial data from Asia claims 40–70% efficacy in children aged 2–14 years. This is a substantial advance in dengue prevention but clearly falls short of the levels of protection required for a standalone intervention. The dengue vaccine initiative and other consortia have emphasised the benefits of integrating vaccines with mosquito control measures, which infers that vector control can bolster the effect of imperfect vaccines.